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Abstract 40 
Purpose: To assess preoperative features of patients with idiopathic macular hole (IMH) and 41 
vitreomacular adhesion (VMA) treated with Ocriplasmin (OCP) that can predict successful 42 
closure.  43 
Method: Data was prospectively collected on all patients with IMH treated with OCP in 3 44 
British ophthalmic centres. Several preoperative variables were recorded including the IMH 45 
base diameter (BD), minimum linear diameter (MLD) and VMA width measured on spectral 46 
domain optical coherence tomography. Several other IMH indices were derived including a 47 
‘width factor’, defined as the BD minus the MLD in microns.  The occurrence of VMA release 48 
and hole closure were used as the main outcome measures.  49 
Results: Thirty three patients in total with IMH were treated with OCP. Two patients 50 
developed rhegmatogenous retinal detachment and were excluded. The mean age of the 51 
remaining 31 patients was 71 years, and 71% were female. VMA release occurred in 19 of 52 
the 31(61%) patients and macular hole closure in 11(35%). Width factor was the most 53 
predictive feature for closure on multivariate analysis.  The deviance R squared was 67% 54 
(p<0.001). An IMH with a width factor of less than 60 microns had a 95% certainty of closure 55 
whilst if greater than 290 microns then there was less than a 5% chance of closure. Neither 56 
VMA width nor MLD alone was associated with VMA release or closure.   57 
Conclusions:  Patients with macular holes where the BD was close in size to the MLD had an 58 
improved probability of closure than holes with wider base configurations.  59 
  60 
 Introduction 61 
Ocriplasmin (OCP) (Jetrea, Thrombogenics, The Netherlands) has been licensed for the 62 
treatment of patients with symptomatic vitreomacular adhesion (VMA) including those with 63 
full thickness idiopathic macular holes (IMH). The efficacy of OCP for patients with IMH and 64 
VMA was demonstrated in 2 phase 3 clinical trials, the Microplasmin for Intravitreous 65 
Injection–Traction Release without Surgical Treatment (MIVI-TRUST) trials, which recorded 66 
an overall FTMH closure rate of 40.6% (43 of 106 patients) in the OCP arms compared to 67 
10.6% (5 of 47) in the control vehicle injected arms.1  Closure was higher in the 48 patients 68 
with holes with a minimum linear diameter of less than 250 microns at 58.3% compared to 69 
the 38 patients with medium sized holes (250-400 microns) at 36.8%.2 None of the 19 70 
patients included in the study with large holes (>400 microns) achieved closure.2 Post 71 
marketing studies have generally not matched these results, with lower levels of closure and 72 
less concordance with hole size.3-7 The largest independent study to date by Sharma et al. 73 
included 15 FTMH and had a 27% closure rate with 33% in small holes and 25% in medium 74 
sized holes.3 Other features have been identified as being prognostic for VMT release with 75 
OCP including younger age, phakic status and absence of ERM but not specifically for 76 
macular hole closure.2,8 We prospectively collected data on patients with IMH and VMA 77 
treated with OCP to assess if any specific baseline parameters could predict successful 78 
closure.  79 
 80 
Method 81 
Data on all  patients treated with OCP for IMH with VMA during the period August 2013 to 82 
March 2015 in three large ophthalmic treatment centres clustered in the North East of 83 
England were prospectively collected using a  jointly agreed  data collection form. Patients 84 
were eligible for treatment with OCP as per UK National Institute for Health and Care 85 
Excellence (NICE) criteria based on the presence of VMA, the width of the hole less than 86 
400 microns and absence of epiretinal membrane.9,10  Eight surgeons carried out the 87 
treatment and all patients had 125 micrograms of OCP delivered by intravitreal injection as 88 
per manufacturer’s instructions. Patients had spectral domain optical coherence 89 
tomography (SD OCT) performed immediately pre injection to confirm the persistence of 90 
VMA 11 and from which a variety of OCT parameters were measured.  The macular hole 91 
minimum linear diameter (MLD) in the SD OCT slice with the maximum hole dimensions 92 
was measured using a standardised technique as described by Decroos et al, 12 as well as 93 
the base diameter (BD), height (H) and maximum horizontal width (W) of the VMA by one 94 
observer masked to the outcome. Two different SD OCT devices were used: a Heidelberg 95 
Spectralis HRA +SDOCT (Heidelberg engineering, Heidleberg, Germany) was used in two 96 
centres and a  Topcon 3D SDOCT-2000 (Topcon Corporation, Tokyo, Japan) in the other, 97 
both with  high density scanning protocols. Best corrected visual acuity, age, sex, and 98 
phakic status at baseline were also collected.  Patients were assessed post injection to 99 
assess VMA release and IMH closure, defined as the absence of a full thickness retinal 100 
defect. To be eligible for inclusion in the final analysis patients had to have had SD OCT 101 
performed at least 4-6 weeks post injection. Snellen visual acuities were converted to 102 
logMAR for analysis.  The baseline measurements were used to calculate the following, 103 
previously described, indices; macular hole index (MHI which is H/BD), diameter hole index 104 
(DHI which is MLD/BD) and tractional hole index (THI which is H/MLD) 13, 14 as well as a 105 
simple calculation of the BD minus the MLD which we termed ‘width factor’. Under UK 106 
guidelines the analysis was classified as a service evaluation and as such did not require 107 
ethical approval. 108 
 109 
Statistical analysis 110 
Descriptive and statistical analysis was performed using Minitab 17 (Minitab Ltd, Coventry, 111 
UK). Patients’ demographic baseline characteristics are presented in terms of mean, 112 
standard deviation (SD) and range or percentage as appropriate. When comparing groups 113 
mean and standard errors are presented.   T-tests were used to compare continuous 114 
variables and chi squared tests on the discrete variables. LogMAR was dichotomised to 115 
greater or less than 0.8 (6/36) as it had a limited discrete scale and the frequencies were too 116 
small to use all the categories.  The derived ratios MHI, DHI, THI had asymmetric 117 
distributions and hence their square roots were used which normalised them. Binary logistic 118 
regression with a stepwise option was used to distinguish the most important variables and 119 
present a predictive model  120 
 121 
 122 
Results 123 
There were 33 patients (33 eyes) in total treated during the study period. Two patients 124 
experienced rhegmatogenous retinal detachment on day 5 and day 21 respectively and 125 
were excluded from further analysis.  126 
The baseline characteristics of the 31 included patients are shown in table 1. All patients 127 
were white British in ethnicity. Twelve of the patients had holes with a MLD of less than 250 128 
microns and 19 were between 250-400 microns.  Overall 19 (61%) patients experienced 129 
VMA release by 1 month postoperatively and 11(35%) patients had hole closure. Closure 130 
occurred in 6 of the 12(50%) patients with holes with a MLD of less than 250 microns and 5 131 
of the 19 (26%) between 250-400 microns. In the eight patients with VMA release but 132 
without hole closure, 5 were less than 250 microns and 3 were more than 250 microns in 133 
MLD.  There were no cases of VMA release or closure after 1 month and there were no 134 
patients who had closure without VMA release.     135 
Several of the baseline characteristics were highly correlated (Table 2). The correlation 136 
between the baseline characteristics derived from the same variables were particularly high.  137 
For example the correlation between base diameter and width factor (BD-MLD), and the 138 
square root of ratios DHI (MLD/BD), and MHI (H/BD) were 0.96, 0.82, 0.62 respectively. 139 
The characteristics of the patients divided by closure are shown in table 3.   140 
On univariate analysis pre-operative visual acuity ≥0.8 (≥6/36) and height were significantly 141 
associated with closure; patients with a visual acuity of worse than 6/36 or thicker retinas 142 
were less likely to close than those with better vision than 6/36 and thinner retinas. 143 
However from table 3 it is clear that BD, and its derived variables, was the key factor for 144 
predicting closure. Importantly MLD was not significantly predictive of closure. When all 4 145 
BD based variables were fitted into a model using binary logistic regression, width factor 146 
(BD-MLD) was the most predictive of outcome. Using multivariate analysis width factor was 147 
significantly associated with closure (P<0.001). The deviance R squared was 67. 2% for width 148 
factor predicting closure (Figure 1). If the width factor was <60, there was a 95% certainty of 149 
closure. If the width factor was 175, there was a 50% chance of closure and if the width 150 
factor was >290 then there was less than a 5% chance of closure (Figure 2). If BD alone is 151 
used the R squared value of the model was lower at 49.3% and hence less predictive of 152 
closure.  Using this model the 95, 50 and 5% BD measurement values predictive of closure 153 
were 179, 424 and 669 microns. 154 
 155 
For VMA release we found that only BD and its derived variables were significantly 156 
associated with release and the most predictive factor was MHI (p<0.001). We found no 157 
significant association between the width of VMA and the occurrence of VMA release. The 158 
mean VMA width measured  299 microns (SE 29) in those with release and 360 microns (SE 159 
38) in those without release (p=0.20). Similarly age and lens status were not found to be 160 
significantly associated with release.  Using binary logistic regression the deviance R squared 161 
was 35.2% for MHI predicting VMA separation.  MLD was again not significantly associated 162 
with release (p=0.23) 163 
 164 
 165 
 166 
 167 
  168 
Discussion 169 
Ocriplasmin is the first approved non vitrectomising technique to close macular holes. When 170 
successful the results can be excellent with approximately 50% of patients with closure 171 
gaining 3 or more lines of vision, and avoiding some of the side effects of vitrectomy 172 
including cataract production.1,2 It is however a relatively  expensive treatment with an 173 
emerging adverse event profile including retinal detachment, seen in two patients in this 174 
series,  and acute visual loss with outer retinal dysfunction.15-19 It is therefore important to 175 
identify features which could predict success.  176 
 177 
The overall closure rate in this series of 35% is fairly similar to that found in other studies. 178 
Importantly however we found a morphological feature that was highly predictive of closure 179 
namely what we termed width factor: the BD minus the MLD. The smaller the BD diameter 180 
was, relative to the MLD, the greater the chance of closure.  BD alone was less predictive of 181 
closure and importantly MLD on its own was not significantly predictive of closure although 182 
no holes greater than 400 microns in MLD were included based on trial results, licensing and 183 
local funding. Similarly patients with any ERM were excluded as this has been shown to be 184 
related to unsuccessful VMA release.8     185 
 186 
In the MIVI TRUST trials 19 out of the 43 with non surgical MH closure did not have VMA 187 
release by day 28 or month six.2 We did not have any patients who closed without VMA 188 
release.  We observed 8 patients who experienced VMA release without hole closure. 189 
Presumably in these patients other factors play a role in persistent hole opening including 190 
tangential traction related to residual vitreous tissue on the ILM although we have recently 191 
shown that this is less after ocriplasmin treatment for IMH.20 The ILM itself contributes very 192 
significantly to the rigidity of the retina 21 and its removal is known to improve macular hole 193 
closure.22 Atomic force measurements have shown that ILM stiffness is greater on the 194 
retinal side than the vitreous side accounting for its tendency to scroll upwards as peeled 195 
and as such its presence will act to maintain hole opening.23 Changes in retinal morphology 196 
are known to occur with advancing macular hole formation, such as those recently 197 
described by Woon et al. and ascribed to the central fovea having a bistable structure.24 198 
They observed that BD increases to a far greater extent than MLD as holes enlarge and this 199 
may underpin our observation that holes with narrow BD relative to MLD were most likely 200 
to close  being at an earlier stage in their development.  It may be that an interplay between 201 
macular hole size and ILM characteristics in individual patients define whether closure can 202 
occur with VMA release alone or indeed the need for ILM peeling with surgery.  203 
 204 
Another factor derived from BD, MHI was the most predictive variable for VMA release. The 205 
narrower the BD was relative to the height of the hole the greater the likelihood of VMA 206 
release. MHI has been proposed to represent the putative tangential and anteroposterior 207 
vitreomacular traction thought to be acting on the fovea and causing the macular hole to 208 
develop.13 The association with MHI suggests that holes with greater presumed tractional 209 
forces release VMA more readily. By distinction VMA width which ranged in the study from 210 
102 to 596 microns was not predictive of release. Indeed the case with a 102 micron VMA 211 
did not release. Moreover a range of factors will affect local VMA release including the dose 212 
of OCP reaching the area of the VMA and local cellular proliferation around the area of VMA 213 
not detectable on SD OCT.  214 
 215 
The study has several limitations. Although the sample size in this paper is larger than other 216 
independent series, it is still relatively small. However, despite that, highly significant effects 217 
were found. It is possible that in a much larger study additional variables would become 218 
significant in predicting VMA release and closure. Two different OCT machines were used 219 
but both were spectral domain and measurements were made manually by one observer 220 
avoiding segmentation differences.25 Measurement variability is a known issue however 221 
when assessing macular holes and it  is possible that the results would not be the same 222 
using different machines and observers. 26 All patients were white Caucasian and the results 223 
may not be applicable to other populations. We used macular hole closure as our main 224 
endpoint rather than visual acuity as although the ultimate aim of treatment is to improve 225 
vision, closure is an well-defined criteria for success. 226 
  227 
In conclusion we found that the width factor, calculated by subtracting MLD from BD, was 228 
highly prognostic for predicting closure in patients with full thickness idiopathic macular 229 
holes treated with ocriplasmin. Further studies to validate this finding are needed.  230 
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Legends for figures  344 
Figure 1 345 
Graph of probability of closure versus width factor 346 
 347 
Figure 2 348 
Representative example of 3 cases with successful primary closure after Ocriplasmin (a,b,c) and 3 349 
cases without closure (d,e,f) with corresponding measurements 350 
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